Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.
Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
Comparative clinical characteristics of early- and adult-onset multiple sclerosis patients with seizures.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Changes in the expression of the glutamate transporter EAAT3/EAAC1 in health and disease.
The influence of vitamin D on postpartum relapse and quality of life in pregnant multiple sclerosis patients.
Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease.
Clinical applications at ultrahigh field (7 T). Where does it make the difference?
Measuring Gray Matter and White Matter Damage in MS: Why This is Not Enough.
Categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis.
Office immunotherapy in chronic inflammatoryh demyelinating polyneuropathy and multifocal motor neuropathy.
Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis.
The role of CNS TLR2 activation in mediating innate versus adaptive neuroinflammation.
Resistant Strains of Enterotoxigenic Staphylococcus aureus; Unknown Risk for Multiple Sclerosis Exacerbation.
Evidence for the Importance of Vitamin D Status in Neurologic Conditions.
The Ins and Outs of Polarized Axonal Domains.
Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems.
MULTIPLE SCLEROSIS IN CHILDHOOD.
Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis?
A case of demyelinating polyneuropathy associated with anti-myelin-associated glycoprotein antibodies with progressive quadriparesis and respiratory failure.
Stable biomarker for plastic microglia.
Improved neurite outgrowth on central nervous system myelin substrate by siRNA-mediated knockdown of Nogo receptor.
Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus (TMEV) infection.
Secondary B Cell Receptor Diversification Is Necessary for T Cell Mediated Neuro-Inflammation during Experimental Autoimmune Encephalomyelitis.
Multiple sclerosis lymphocytes upregulate A2A adenosine receptors which are anti-inflammatory when stimulated.
Pages
« first
‹ previous
…
652
653
654
655
656
657
658
659
660
…
next ›
last »